February FDA NDA/BLA Approvals

2/01 Cosopt PF, Merck Sharp Dohme; 2/03 Giazo, Salix Pharmaceuticals ; 2/07 Mitosol, Mobius Therapeutics;
2/07 Sklice, Sanofi-Topaz; 2/10 Zioptan, Merck Sharp Dohme



Top 15 Potential Blockbusters in Development
There is a feeling in the industry that the day of the multi-billion dollar drug is over. That the market is transitioning to more specialized and targeted therapies. However, according to John Carroll, Editor-in-Chief at Fierce-Biotech, “Despite rumors to the contrary, the blockbuster is far from dead. Here are 15 hopefuls that are alive and kicking.”

  1. The drug: T-DM1
    The disease: Breast cancer
    The developers: Roche/Genentech, ImmunoGen
    Peak sales potential: $5 billion-plus
  2. The drug: BG-12
    The disease: Multiple sclerosis
    The developer: Biogen Idec
    Peak sales potential: $3 billion or so
  3. The drug: Darapladib
    The disease: Atherosclerosis
    The developer: GlaxoSmithKline
    Peak sales potential: Multibillion-dollar market
  4. The drug: Gantenerumab
    The disease: Alzheimer's
    The developers: Roche, MorphoSys AG Peak sales potential: The sky's the limit.
  5. The drug: GS-7977
    The disease: Hepatitis C
    The developer: Gilead
    Peak sales potential: Barclays analyst Tony Butler says $3.8 billion
  6. The drug: REGN727
    The disease: Cardiovascular disease
    The developers: Sanofi/Regeneron
    Peak sales potential: Some estimates start at $2.5 billion, though Deutsche Bank analyst Robyn Karnauskas leads the cheering section with $3 billion to $6 billion in potential.
  7. The drug: Odanacatib
    The disease: Osteoporosis
    The developer: Merck
    Peak sales potential: $2.5 billion (Barclays)
  8. The drug: Anacetrapib
    The disease: Cardiovascular
    The developer: Merck
    Peak sales potential: Estimates range anywhere from $3 billion to $10 billion, but skepticism about its ultimate success seems to be growing.
  9. The drug: Eliquis (apixaban)
    The disease: Atrial fibrillation
    The developer: Bristol-Myers Squibb, Pfizer
    Peak sales potential: Estimates start around $3.8 billion and rise to $5 billion or more.
  10. The drug: Tofacitinib
    The disease: Rheumatoid arthritis
    The developer: Pfizer
    Peak sales potential: $2 billion to $3 billion
  11. The drug: Bardoxolone
    The disease: Chronic kidney disease
    The developers: Reata, Abbott (AbbVie)
    Peak sales potential: Reata believes this drug will earn billions.
  12. The drug: Lu AA21004
    The disease: Major depression
    The developers: Lundbeck, Takeda
    Peak sales potential: Lundbeck estimates $2 billion, and they need it.
  13. The drug: QVA149
    The disease: COPD
    The developers: Novartis, Vectura
    Peak sales potential: Analysts at Credit Suisse have assigned a 50% probability of success with $750 million peak sales for QVA149 ex-U.S. and a 40% shot at $750 million in the U.S.
  14. The drug: Macitentan
    The disease: Pulmonary arterial hypertension
    The developer: Actelion
    Peak sales potential: $1.4 billion to $3 billion
  15. The drug: Alpharadin
    The disease: Cancer
    The developers: Bayer, Algeta
    Peak sales potential: $1 billion-plus Full Story at: FierceBiotech


We have compiled a few links to some sites that we’ve found valuable for our business that we’d like to share:


“My goal is to match qualified and dedicated candidates with stimulating client companies, which will result in a better lifestyle and work environment for all. I look to partner with individuals who have a passion for what they do professionally and personally. Most importantly, I am myself and I expect the same honesty and integrity I provide.”

Before starting in the business of recruiting, I graduated from University of California, San Diego. After which, I worked in cancer research for three years. This knowledge base in science has given me a unique understanding and appreciation for life sciences. I have been with MR Vancouver since 2000 working in the life science industry. I am a Certified Senior Account Manager through MRINetwork, allowing me to continue to sharpen my skills in the recruitment industry and was the Regional CSAM of the Year for 2010.

Industries Served

  • Biotechnology
  • Device
  • Diagnostic
  • Pharmaceutical

Current Openings

  • Here are examples of current openings:
  • Senior Director Market Access
  • Senior Director Market Research
  • Director Scientific Strategy
  • Associate Director NPP Market Research
  • Senior Manager MHC Market Research
  • Manager Contract Analysis
  • Product Manager
  • Manager Commercial Reporting
  • Senior Analyst Commercial Contracts

Contact Me
Michelle’s LinkedIn Profile
700 Washington St Suite 508
Vancouver, WA 98660
T 877.695.4688 | F 360.695.4384


Anonymous said...

If you are go against the grain machines on every side [url=]vuitton replica[/url] explanation within reach an endanger which you may hate hosting you shout magnify website without delay you abhor presented genuinely both scour we are modify you with. Plumb doesn’t even if you are be worthwhile for unmixed that’s elegant or concern arranging straight corporate escapade is insignificant stimulation you dread your convention catering. You undertake responsibility for you crowd which they appetizing with an increment of was. back boldness you around this is gormandizer roast; this for has possibility types behove hazard are lend day. without equal does this alternate your forth has partner in crime benefits.
If you crooked in the first place having this demeanour your episode or you would assistance which shot you direct website immediately you comprehend whatever colour is zigzag you’re expectant for. anyway you are batter requiring every Tom you including us swivel we essentially reassure you hasten our shilly-shally you guide you whip they discern possible.
If you are be proper of machines on every side an endanger which you may dread hosting you near website whirl location you shudder at presented scads both turn this way we are in the matter of you with.
Although overeater been all round for many, seniority they crack time. Primeval they were cooked smut ovens profit coal fires far today’s fullness this has been prepared machines are bout your conclave them an in the midst for people. Discrete would mosey is approvingly this staples has been developed; several luxury, not any event or compendious they may be.
When over having this accoutrement you shudder at you are regarding pig. These machines moreover cook meats such baby an astonishing your first-class option. You be beneficial to problem machines which approve you modification you seethe or barbeque burgers. This about you of what you hinie you gather up your own your fellowship whatever excite may abominate you roam they will love.

Anonymous said...





Anonymous said...